136 related articles for article (PubMed ID: 21297328)
1. A rare lung nodule consisting of adenocarcinoma and amyloid deposition in a patient with primary systemic AL amyloidosis.
Miyazaki D; Yazaki M; Ishii W; Matsuda M; Hoshii Y; Nara K; Nakayama J; Ikeda S
Intern Med; 2011; 50(3):243-6. PubMed ID: 21297328
[TBL] [Abstract][Full Text] [Related]
2. Regression of gastroduodenal amyloid deposition in systemic AL amyloidosis after intensive chemotherapies.
Katoh N; Matsuda M; Tsuchiya-Suzuki A; Ikeda S
Br J Haematol; 2011 May; 153(4):535-8. PubMed ID: 21275957
[No Abstract] [Full Text] [Related]
3. Lung adenocarcinoma expressing receptor for advanced glycation end-products with primary systemic AL amyloidosis: a case report and literature review.
Okamoto S; Togo S; Nagata I; Shimizu K; Koinuma Y; Namba Y; Ito J; Uekusa T; Takahashi K
BMC Cancer; 2017 Jan; 17(1):22. PubMed ID: 28056871
[TBL] [Abstract][Full Text] [Related]
4. Rapid reversal of nephrotic syndrome due to primary systemic AL amyloidosis after VAD and subsequent high-dose chemotherapy with autologous stem cell support.
Sezer O; Schmid P; Shweigert M; Heider U; Eucker J; Harder H; Sinha P; Radtke H; Possinger K
Bone Marrow Transplant; 1999 May; 23(9):967-9. PubMed ID: 10338056
[TBL] [Abstract][Full Text] [Related]
5. Regression of renal amyloid deposits by VAD therapy plus autologous stem cell transplantation in a patient with primary AL amyloidosis.
Toriu N; Sawa N; Hiramatsu R; Mizuno H; Ikuma D; Sekine A; Hayami N; Sumida K; Yamanouchi M; Hasegawa E; Hoshino J; Takaichi K; Wake A; Ohashi K; Fujii T; Ubara Y
CEN Case Rep; 2020 Feb; 9(1):6-10. PubMed ID: 31522370
[TBL] [Abstract][Full Text] [Related]
6. Successful treatment of primary AL amyloidosis by VAD therapy, high-dose melphalan, and autologous peripheral stem cell transplantation.
Yamazaki O; Ubara Y; Suwabe T; Nakanishi S; Hoshino J; Sawa N; Hayami N; Yamanouchi M; Takemoto F; Kenmei T; Masuoka K; Oohashi K
Clin Exp Nephrol; 2009 Oct; 13(5):522-525. PubMed ID: 19499180
[TBL] [Abstract][Full Text] [Related]
7. Amyloid deposition of systemic myeloma-associated amyloidosis excludes actinic elastotic material.
Wada N; Fujimoto N; Komatsu T; Tajima S; Ishibashi A
Eur J Dermatol; 2002; 12(6):607-8. PubMed ID: 12459542
[TBL] [Abstract][Full Text] [Related]
8. Serum levels of free light chain before and after chemotherapy in primary systemic AL amyloidosis.
Matsuda M; Yamada T; Gono T; Shimojima Y; Ishii W; Fushimi T; Sakashita K; Koike K; Ikeda S
Intern Med; 2005 May; 44(5):428-33. PubMed ID: 15942088
[TBL] [Abstract][Full Text] [Related]
9. [IgM-lambda multiple myeloma presenting with systemic amyloidosis].
Higeta D; Yokohama A; Osaki Y; Tahara K; Mawatari M; Sekigami T; Koiso H; Saito T; Uchiumi H; Handa H; Karasawa M; Murakami H; Hirato J; Tsukamoto N; Nojima Y
Rinsho Ketsueki; 2009 Dec; 50(12):1711-4. PubMed ID: 20068279
[TBL] [Abstract][Full Text] [Related]
10. Nephrotic syndrome due to primary AL amyloidosis, successfully treated with VAD and subsequent high-dose melphalan followed by autologous peripheral blood stem cell transplantation.
Gono T; Matsuda M; Dohi N; Hoshi K; Tada T; Sakashita K; Koike K; Aizawa M; Ikeda S
Intern Med; 2003 Jan; 42(1):72-7. PubMed ID: 12583623
[TBL] [Abstract][Full Text] [Related]
11. The treatment of nephrotic syndrome caused by primary (light chain) amyloid with vincristine, doxorubicin and dexamethasone.
Wardley AM; Jayson GC; Goldsmith DJ; Venning MC; Ackrill P; Scarffe JH
Br J Cancer; 1998 Sep; 78(6):774-6. PubMed ID: 9743299
[TBL] [Abstract][Full Text] [Related]
12. Therapeutic outcome of cyclic VAD (vincristine, doxorubicin and dexamethasone) therapy in primary systemic AL amyloidosis patients.
Tazawa K; Matsuda M; Yoshida T; Gono T; Katoh N; Shimojima Y; Ishii W; Fushimi T; Koyama J; Ikeda S
Intern Med; 2008; 47(17):1517-22. PubMed ID: 18758127
[TBL] [Abstract][Full Text] [Related]
13. Nephrotic syndrome due to primary systemic AL amyloidosis, successfully treated with VAD (vincristine, doxorubicin and dexamethasone) alone.
Matsuda M; Gono T; Katoh N; Yoshida T; Tazawa K; Shimojima Y; Ishii W; Fushimi T; Ikeda S
Intern Med; 2008; 47(6):543-9. PubMed ID: 18344643
[TBL] [Abstract][Full Text] [Related]
14. The Long-term Outcomes after VAD plus SCT Therapy in a Patient with AL Amyloidosis and Severe Factor X Deficiency.
Iwadate D; Hasegawa E; Hoshino J; Hayami N; Sumida K; Yamanouchi M; Sekine A; Kawada M; Hiramatsu R; Suwabe T; Sawa N; Yuasa M; Wake A; Fujii T; Ohashi K; Takaichi K; Ubara Y
Intern Med; 2018 Mar; 57(5):701-706. PubMed ID: 29093408
[TBL] [Abstract][Full Text] [Related]
15. [Improved prognosis of generalized AL-amyloidosis in a patient with multiple myeloma treated according to the VAD protocol].
Sarkisova IA; Rameev VV; Kozlovskaia LV; Andreeva NE
Ter Arkh; 2003; 75(8):81-2. PubMed ID: 14520860
[No Abstract] [Full Text] [Related]
16. [A patient with AL amyloidosis and severe factor X deficiency has been in complete haematological remission with normal factor X activity for 7 years following high-dose chemotherapy. A case study and literature review].
Adam Z; Matýková M; Krejcí M; Pour L; Kissová J; Slechtová M; Chlupová G; Stavarová Y; Simonides J; Penka M; Mayer J; Hájek R
Vnitr Lek; 2010 Jan; 56(1):67-78. PubMed ID: 20184115
[TBL] [Abstract][Full Text] [Related]
17. Diagnosis and treatment of AL amyloidosis.
Sezer O; Eucker J; Jakob C; Possinger K
Clin Nephrol; 2000 Jun; 53(6):417-23. PubMed ID: 10879660
[TBL] [Abstract][Full Text] [Related]
18. AH amyloidosis associated with an immunoglobulin heavy chain variable region (VH1) fragment: a case report.
Miyazaki D; Yazaki M; Gono T; Kametani F; Tsuchiya A; Matsuda M; Takenaka Y; Hosh Y; Ikeda S
Amyloid; 2008 Jun; 15(2):125-8. PubMed ID: 18484339
[TBL] [Abstract][Full Text] [Related]
19. A case of primary (AL) amyloidosis with predominantly vascular amyloid deposition in the kidney.
Murakami Y; Hattori S; Sugiyama F; Yoshikawa K; Sugiura T; Matsushima H
CEN Case Rep; 2015 Nov; 4(2):151-156. PubMed ID: 28509092
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of intensive chemotherapy in AL amyloidosis: usefulness of flow cytometric analysis of plasma cells in bone marrow.
Matsuda M; Gono T; Shimojima Y; Sakashita K; Koike K; Ikeda S
Amyloid; 2003 Dec; 10(4):250-6. PubMed ID: 14986484
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
